guest ::
| Home > Publications Database > Long‐Read Sequencing Reveals Ancestral intragenic APOE Haplotypes with Distinct Roles in Alzheimer’s Disease > print |
| Home > Publications Database > Long‐Read Sequencing Reveals Ancestral intragenic APOE Haplotypes with Distinct Roles in Alzheimer’s Disease > print |
| 001 | 283113 | ||
| 005 | 20260103103703.0 | ||
| 024 | 7 | _ | |a 10.1002/alz70861_108005 |2 doi |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00009 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ruiz, Agustin |b 0 |
| 111 | 2 | _ | |a Alzheimer’s Association International Conference |g AAIC 25 |c Toronto |d 2025-07-27 - 2025-07-31 |w Canada |
| 245 | _ | _ | |a Long‐Read Sequencing Reveals Ancestral intragenic APOE Haplotypes with Distinct Roles in Alzheimer’s Disease |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1767354741_32513 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |m journal |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a Background:The apolipoprotein E (APOE) ε4 allele remains the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), yet the marked variability in its pathogenicity suggests underlying genetic complexity. Historically, efforts to resolve the intragenic architecture of APOE have been hampered by the limitations of conventional genotyping and short-read sequencing, as well as the presence of homoplasy in common intragenic markers—misleading similarities arising from convergent variants.Objective:We leveraged Oxford Nanopore Technology (ONT) to phase intragenic APOE variants, resolve homoplasy, and examine the impact of phased haplotypes on cerebrospinal fluid (CSF) APOE protein levels and AD progression.Methods:Using long-read sequencing in a Spanish memory clinic cohort (n = 1,267), we reconstructed full-length 4 kb APOE haplotypes, identifying 59 unique configurations grouped into five major haplogroups. Common intragenic variants defined ancestral ε4 (4A, 4B) and ε3 (3A, 3B) haplogroups. These were analyzed for associations with CSF APOE levels (Olink platform) and progression from mild cognitive impairment (MCI) to dementia using adjusted Cox regression models.Results:ONT sequencing successfully resolved homoplasy between the APOE promoter region—particularly at rs405509—and the canonical protein isoforms, uncovering common but functionally distinct ε3A/B and ε4A/B intragenic sub-haplotypes with independent biological effects. Carriers of the ε4A haplotype exhibited significantly lower CSF APOE protein levels (p = 0.004), whereas the ε3B haplotype was associated with elevated CSF APOE protein levels (p = 0.025). Notably, both haplotypes were linked to a slower progression from MCI to AD, independent of APOE genotype, age, sex and core CSF biomarkers.Conclusion:This study redefines the human APOE ε3 and ε4 alleles as genetically heterogeneous entities. Using ONT long-read sequencing, we achieved high-resolution mapping of intragenic haplotypic structure and regulatory variation previously obscured by conventional approaches. This enabled the identification of ancestral haplotypes with distinct functional profiles and potential relevance to Alzheimer’s disease pathogenesis. These findings highlight the importance of incorporating haplotype-level resolution into Alzheimer’s risk assessment, therapeutic targeting, and precision medicine strategies. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 700 | 1 | _ | |a García-González, Pablo |b 1 |
| 700 | 1 | _ | |a Puerta, Raquel |b 2 |
| 700 | 1 | _ | |a Cano, Amanda |b 3 |
| 700 | 1 | _ | |a Olivé, Clàudia |b 4 |
| 700 | 1 | _ | |a Marquié, Marta |b 5 |
| 700 | 1 | _ | |a Valero, Sergi |b 6 |
| 700 | 1 | _ | |a Rosende-Roca, Maitee |b 7 |
| 700 | 1 | _ | |a Sanz, Pilar |b 8 |
| 700 | 1 | _ | |a Alegret, Montserrat |b 9 |
| 700 | 1 | _ | |a Brosseron, Frederic |0 P:(DE-2719)2810593 |b 10 |u dzne |
| 700 | 1 | _ | |a Martino-Adami, Pamela |b 11 |
| 700 | 1 | _ | |a de Rojas, Itziar |b 12 |
| 700 | 1 | _ | |a Heneka, Michael T. |0 P:(DE-2719)2000008 |b 13 |
| 700 | 1 | _ | |a Ramirez, Alfredo |0 P:(DE-2719)2812825 |b 14 |u dzne |
| 700 | 1 | _ | |a Navarro, Arcadi |b 15 |
| 700 | 1 | _ | |a Sáez, María Eugenia |b 16 |
| 700 | 1 | _ | |a Tárraga, Lluís |b 17 |
| 700 | 1 | _ | |a Cavazos, José E. |b 18 |
| 700 | 1 | _ | |a Boada, Mercè |b 19 |
| 700 | 1 | _ | |a Fernández, Victoria |b 20 |
| 700 | 1 | _ | |a Socorro, Alfredo Cabrera |b 21 |
| 773 | _ | _ | |a 10.1002/alz70861_108005 |g Vol. 21, no. S7, p. e108005 |0 PERI:(DE-600)2201940-6 |n S7 |p e108005 |t Alzheimer's and dementia |v 21 |y 2025 |x 1552-5260 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/283113/files/DZNE-2026-00009.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/283113/files/DZNE-2026-00009.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:283113 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2810593 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 14 |6 P:(DE-2719)2812825 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-2719)1011303 |k AG Heneka |l Neuroinflammation, Biomarker |x 0 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-2719)1011303 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|